High Times
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

Hey Doog, long time no see, lol. Just

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
dtstx Member Profile
 
Followed By 18
Posts 2,282
Boards Moderated 0
Alias Born 07/09/06
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/18/2018 5:20:51 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/17/2018 2:54:24 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/17/2018 6:06:31 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/16/2018 5:31:22 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/16/2018 5:29:03 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2018 5:28:49 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/15/2018 3:52:11 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/15/2018 3:51:43 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 10/15/2018 7:35:39 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/12/2018 4:51:41 PM
Registration of Additional Securities (up to 20%, Foreign Issuer) (f-1mef) Edgar (US Regulatory) - 10/12/2018 6:08:11 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/12/2018 6:07:52 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 10/11/2018 6:42:39 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/11/2018 6:36:13 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/11/2018 6:06:49 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 10/5/2018 5:43:55 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/5/2018 7:16:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/5/2018 7:08:59 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 10/5/2018 6:19:33 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/1/2018 8:12:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/1/2018 8:06:15 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/21/2018 4:43:58 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 9/21/2018 4:35:33 PM
Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 9/20/2018 5:37:43 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/13/2018 9:17:54 AM
dtstx   Wednesday, 11/08/17 12:34:52 PM
Re: doogdilinger post# 31168
Post # of 37542 
Hey Doog, long time no see, lol. Just checking in as we both had been in this company for 5-6yrs. I had made the decision to unload completely upon the Glucophage acceptance run-up on 2-24-17, in the 2.55-2.85 range. Coincidentally that was 1 yr. to the day that the Keppra acceptance was announced with no movement on commercialization of that product. I wasn't optimistic about Glucophage fairing any better with the companies history. At my peak I had well over 300k shares so the run-up helped me unload as we were around the $2 range previously.

I had bowed out gracefully still hoping this company could turn the corner for the sake of the good people still invested here. I will say for the record I did not envision the Adcom results but it most certainly reflects a pattern.

I guess for me, being invested in a company for so long, I let my vision cloud my better judgement. That being said my best to those still invested here. I think new money can make a profit at these levels in due time.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist